Taysha Gene Therapies Income Statement (2019-2026) | TSHA

Income Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
4.71M2.40M4.75M3.60M3.41M1.11M1.79M2.02M2.30M1.99M1.21M
Operating items
Research & Development (Quarter)
30.64M39.53M-91.03M38.18M23.51M16.77M12.71M12.51M19.79M11.79M-40.60M20.66M15.07M14.95M-49.68M15.56M20.14M25.75M-58.45M33.81M
Selling, General & Administrative (Quarter)
10.13M11.15M11.81M11.47M9.87M8.68M7.34M8.75M5.99M8.59M-20.73M7.08M7.34M7.90M6.63M8.16M8.60M8.28M8.83M9.68M
Other Operating Expenses (Quarter)
128.94M36.42M0.62M81.17M4.84M65.00M83.40M
Operating Expenses (Quarter)
40.77M50.68M49.72M49.65M33.37M25.46M56.47M21.27M25.78M21.00M19.85M27.74M22.41M27.69M21.95M23.72M28.74M34.02M33.78M43.49M
Operating Income (Quarter)
-40.77M-50.68M-49.72M-49.65M-33.37M-25.46M-53.97M-16.56M-23.38M-16.25M-16.25M-24.33M-21.30M-25.90M-19.93M-21.42M-26.75M-34.02M-28.30M-43.49M
EBIT (Quarter)
-40.77M-50.68M-49.72M-49.65M-33.37M-25.46M-53.97M-16.56M-23.38M-16.25M-16.25M-24.33M-21.30M-25.90M-19.93M-21.42M-26.75M-34.02M-28.30M-43.49M
Non-operating items
Interest & Investment Income (Quarter)
1.11M1.92M1.69M1.44M2.11M1.70M1.33M1.86M3.17M2.87M2.59M
Other Non Operating Income (Quarter)
-0.00M-0.00M-0.01M-0.01M0.00M100.46M34.74M0.34M0.04M-0.08M-0.18M0.01M0.27M-0.04M0.74M-0.03M
Non Operating Income (Quarter)
0.04M-0.51M-1.40M-0.67M0.03M-1.07M0.20M-1.06M-1.21M-100.84M63.99M0.27M0.37M0.37M1.15M-0.11M-0.13M1.29M0.45M1.08M
Net income details
EBT (Quarter)
-45.27M-51.22M-75.24M-50.63M-34.12M-26.54M-56.01M-28.18M-55.53M-26.04M-15.61M-36.93M-29.45M-52.88M-14.35M-28.59M-51.17M-61.99M-25.44M-98.11M
Profit After Tax (Quarter)
-40.93M-51.19M-50.39M-50.32M-34.09M-26.53M-55.08M-17.62M-24.60M-117.09M47.74M-24.06M-20.93M-25.52M-18.79M-21.53M-26.88M-32.73M-27.85M-42.41M
Income from Continuing Operations (Quarter)
-45.27M-51.22M-75.24M-50.63M-34.12M-26.54M-56.01M-28.18M-55.53M-26.04M-15.61M-36.93M-29.45M-52.88M-14.35M-28.59M-51.17M-61.99M-25.44M-98.11M
Consolidated Net Income (Quarter)
-45.27M-51.22M-75.24M-50.63M-34.12M-26.54M-56.01M-28.18M-55.53M-26.04M-15.61M-36.93M-29.45M-52.88M-14.35M-28.59M-51.17M-61.99M-25.44M-98.11M
Income towards Parent Company (Quarter)
-45.27M-51.22M-75.24M-50.63M-34.12M-26.54M-56.01M-28.18M-55.53M-26.04M-15.61M-36.93M-29.45M-52.88M-14.35M-28.59M-51.17M-61.99M-25.44M-98.11M
Net Income towards Common Stockholders (Quarter)
-40.93M-51.19M-50.39M-50.32M-34.09M-26.53M-55.08M-17.62M-24.60M-117.09M47.74M-24.06M-20.93M-25.52M-18.79M-21.53M-26.88M-32.73M-27.85M-42.41M
Additional items
EPS (Basic) (Quarter)
-1.09-1.35-1.34-1.32-0.85-0.65-1.25-0.28-0.38-0.930.41-0.10-0.09-0.10-0.08-0.08-0.09-0.09-0.09-0.12
EPS (Diluted) (Quarter)
-1.09-1.35-1.34-1.32-0.85-0.65-1.25-0.28-0.38-0.930.41-0.10-0.09-0.10-0.08-0.08-0.09-0.09-0.09-0.12
Shares Outstanding (Quarter)
37.48M38.00M37.65M38.17M40.14M40.94M43.95M63.26M64.24M125.70M116.12M231.25M232.82M267.82M250.13M269.31M297.99M353.31M319.71M366.63M
Shares Outstanding (Diluted) (Quarter)
37.48M38.00M37.65M38.17M40.14M40.94M43.95M63.26M64.24M125.70M116.12M231.25M232.82M267.82M250.13M269.31M297.99M353.31M319.71M366.63M
EBITDA (Quarter)
-40.77M-50.68M-49.72M-49.65M-33.37M-25.46M-53.97M-16.56M-23.38M-16.25M-16.25M-24.33M-21.30M-25.90M-19.93M-21.42M-26.75M-34.02M-28.30M-43.49M
Interest Expenses (Quarter)
4.50M0.54M25.51M0.98M0.74M1.08M2.04M11.62M32.15M10.89M1.29M14.29M9.60M29.08M-3.88M8.50M26.27M31.13M0.01M57.21M